INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, characterized by auto-antibody production, complement activation, and immune complex deposition. Auto-antibodies mediate inflammation and various organs damaged through immune complex formation. We already knew that many factors such as infection environment, immunity and many other factor are closely related to cause this disease that adaptive immune system has been the focus of many studies. Current treatment strategies rely heavily...
on corticosteroids. This in turn leads to a cascade of events including increase in infections and malignancies, limit in immunosuppressives, long standing over reliance on corticosteroid therapy. Currently available treatment has involved the use of anti-inflammatory or immunosuppressive non-steroidal anti-inflammatory drugs to deal with different situation. This conventional treatment can be associated with organ damage and not completely effective in many patients, which highlighting a huge need in the area of SLE therapeutics.

In recent years, an increased understanding of the etiopathogenesis has led to development of biologic agents for SLE has been pressing, which may significantly improve the task of treating SLE. Among the biologic agents (atacicept, belimumab, blisibimod, epratuzumab, rituximab, tabalumab) for SLE, it is important to evaluate the efficacy of six biologic agents by systematic review and meta-analysis. Although the efficacy of the multiple biologic agents which used to treat SLE was acceptable, there was no direct comparison between the two interventions. Network meta-analysis (NMA) was an upgrade from traditional meta-analysis (TMA). This study may improve a useful guide for selection of medication treatments for SLE.

**METHODS**

**Search strategy:** The databases searched for this study included PubMed, EMBASE and Cochrane Library, before 4th September 2018, using atacicept, belimumab, blisibimod, epratuzumab, rituximab or tabalumab and SLE. Through literature traceability, we read relevant reviews to view their references and other ways to trap, as much as possible to find all relevant information.

**Inclusion and exclusion criteria:**

The inclusion criteria were as following:

a. Randomized controlled trials
b. Both the experimental group and the control group were SLE patients
c. Data acquisition in around 52 weeks
d. The data of efficacy or adverse reactions are complete and can be analyzed by NMA.
e. Document language was English.

The exclusion criteria were as following:

a. Animal experiments, cross-experimental studies
b. Case reports, systematic reviews
c. Comparison before and after drug treatment, or no data available for analysis
d. The patients with other disease included LN.

**Efficacy evaluation criteria:** Outcome indicators included SRI-4, SRI-6, because of different situations.

The SRI-4 was defined as the following:

a. ≥ 4-point reduction in SELENA-SLEDAI score compared with baseline
b. No worsening (<0.3-point increase from baseline) in Physician’s Global Assessment (PGA)
c. No new British Isles Lupus Assessment Group (BILAG) A organ domain score or two new BILAG B organ domain scores vs baseline.

The SRI-6 was defined as the following:

a. ≥6-point reduction in SELENA-SLEDAI score compared with baseline
b. No worsening (<0.3-point increase from baseline) in Physician’s Global Assessment (PGA)
c. No new British Isles Lupus Assessment Group (BILAG) A organ domain score or two new BILAG B organ domain scores vs baseline.

All analyses were adapted from previous published work. Thus, no ethical approval and patient consent were required.

**Data extraction and quality evaluation:**

Literature search and extraction were performed independently by two reviewers, based on the inclusion and exclusion criteria, include the following:

a. Characteristics of the publication
b. Data quality of the publication
c. Result indicator selection.

**Statistical analysis:** By using commands of the network package in statistical (13.0), the network, evidence contribution, predictive interval (PrI), funnel and ranking plots were constructed. The efficacy of the intervention was ranked based on the surface values under the cumulative ranking (SUCRA) curve. The selected indicator was the count data, and OR is used as the combined effect, with a confidence interval (CI) set to 95%. A value of \( P < 0.05 \) was considered to be statistically significant.

**RESULTS**

A total of 21 RTCs involving 12276 patients were ultimately included in this study. Fig.1 show the select detail of publication includes. The basic characteristics of publications are presented in Table-I.

**Network meta-analysis:** Network plot of six different medicines: Of the 21 publications studies on the
biologic agents for SLE with belimumab were the most frequent, while those on atacicept and rituximab were least. The highest number of subjects was belimumab, while atacicept has the lowest number of this studies (Fig.2). The size of the points in the network graph is proportional to the number of subjects, while the thickness of the line is proportional to the number of studies.

Evidence contribution plot: The direct comparison of placebo alone and belimumab had a 100% effect on the combined results. The direct comparison between placebo and belimumab had a 50% effect on the indirect comparison between belimumab and atacicept. The direct comparison of placebo and belimumab had a 16.7% effect on the results of the NMA (Fig.3).

**Predictive interval plot:** In this study, it is showed that the pooled OR and 95% CI of SLE improvement compared with placebo were 2.03 (1.38-3.00) for belimumab, 1.61 (0.44-5.84) for atacicept, 1.77 (0.80-3.88) for epratuzumab, 1.62 (0.73-3.57) for tabalumab, 1.56 (0.42-5.87) for rituximab, 1.08 (0.44-2.61) for blisibimod, respectively, which indicates an insignificant difference in efficacy except for belimumab. The comparison between other medicines is showed in Fig.4.
Publication bias: Regarding publication bias, all results in the study are basically symmetrical (Fig.5). The probability distribution for each treatment is ranked for their efficacy in SLE according to SUCRA values (Table-II and Fig.4). The order of SUCRA values for different biologic agents was as follows: belimumab (75.0); epratuzumab (62.0); tabalumab (57.1); atacicept (55.1); rituximab (52.6); blisibimod (29.4) placebo (18.7); From this study, the belimumab had the highest probability of being the best treatment in biologic agents.
Fig.5: Funnel plot for publication bias of different medicines.

**DISCUSSIONS**

The study analyzed six biologic agents for SLE in 21 randomized controlled trials. These results showed that the belimumab had the highest probability of being the best treatment compared with other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab), according to network meta-analysis by network diagram makes it more intuitive. Belimumab was more effective highest SUCRA value and highest probability of being the best treatment option, while other medicines indicated an insignificant difference in efficacy.

The SLE is caused by immune complexes depositing on organs and extensive injury were caused. The patients with SLE are characterized by BCR-initiated signaling and IL-6 production, including alter in B cell subset distribution. Therefore, the main clinical strategy for treating SLE was blocking the immune cells stimulating cytokine that affects the development of SLE. The main goal of current treatment strategies, which are not ideal in terms of efficacy and safety, was to use a limited dose of corticosteroids to prevent injury and maintain stable disease control. Biologic agents are being developed to enhance therapeutic efficacy, reduce disease exacerbation and toxicities. Currently, drugs for the SLE treatment evolved from all the patients recommended antimalarial to nonsteroidal anti-inflammatory drugs, glucocorticoids and combination of biologic agents.

It was divided into nine kinds according to its mechanism of action on the following:

a. B cell therapies;

b. Proteasome inhibitors;

c. Inhibition of B/T cell costimulation;

d. Targeting Pdc;

e. Targeting cytokines and their receptors;

f. Targeting the interferons;

g. Targeting the kinases of the intracellular machinery;

h. Targeting the sphingosine-1-phosphate;

i. Other mechanisms of action.

This study analyzed six kinds of biologic agents (atacicept, belimumab, blisibimod, epratuzumab, rituximab, tabalumab), belonging to B cell therapies, to exclude classical immunosuppressive agents, and belimumab may be the most effective.

Belimumab is recombinant human immunoglobulin (Ig) G1-λmAb, which molecular weight of ~147 kDa. It specifically binds to soluble B-lymphocyte stimulator (BLYS), prevents its interaction with other receptors, inhibits B cell apoptosis, stimulates B cells to differentiate into immunoglobulins. BLYS and its receptors (TACI, BCMA and BAFF-R) remain the focal point of therapeutic targets for SLE therapy as

---

**Table-II: SUCRA of SLE treatments.**

| Treatment    | SUCRA (%) | Pr Best | Mean Rank |
|--------------|-----------|---------|-----------|
| Belimumab    | 75        | 20.9    | 2.5       |
| Epratuzumab  | 62        | 17.2    | 3.3       |
| Tabalumab    | 57.1      | 13.1    | 3.6       |
| Atacicept    | 55.1      | 24.1    | 3.7       |
| Rituximab    | 52.6      | 21.7    | 3.8       |
| Blisibimod   | 29.4      | 3       | 5.2       |
| Placebo      | 18.7      | 0       | 5.9       |
autoimmune B cell stimulation and maturation play a major role in the disease onset.\textsuperscript{15} In mouse models of systemic lupus erythematosus, BLYS inhibition delays lupus onset, while in clinical trials, belimumab reduces the number of peripheral CD20 + B cells, which is predominantly naive, significantly reduces SLE disease activity, flare rates and prednisone dose in seropositive patients.\textsuperscript{16–18}

In this study, we focused on SIR response, while adverse reactions also occurred in clinical trials, including headache, fever, nausea, diarrhea and other side effect. The causes of deaths include serious infections, heart disease and suicide. Hypersensitivity reactions may occur, such as immediate withdrawal, and appropriate treatment.\textsuperscript{19}

In addition, the biologic agents except for belimumab (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) were insignificantly superior to placebo. These approaches biologic agents of B cell therapies include: block BLYS, modulate B cell signaling, neutralise soluble BLYS, induce depletion of B cells, block with all three forms of BLYS.\textsuperscript{20–24} The causes of the results are unclear, while biologic agents in treatment of systemic lupus erythematosus are still a long way to go whatever in safe or efficacy.

Limitations of study: In this study, the lack of uniform standards for efficacy evaluation and inconsistent quality of the original publication used may have some effect on the strength of the proposed argument. The results may be affected by inconsistently literature quality, great heterogeneity inherent to SLE, different ethnicity and sample size. Future studies involving high quality RCT and large sample size are needed.

CONCLUSIONS

Biologic agents except for belimumab (atacicept, blisibimod, epratuzumab, rituximab, tabalumab) indicated an insignificant difference in efficacy for the treatment of SLE compared with placebo. Belimumab had the highest probability of being the best treatment for SLE compared with the other biologic agents (atacicept, blisibimod, epratuzumab, rituximab, tabalumab).

Acknowledgements: We especially thank all colleagues who participated for making this study possible. Special thanks to Liang Xu for his encouragement and support.

Grant Support & Financial Disclosures: The project was supported by the National Science Foundation of Anhui Province, China (No. 1608085MH219, 1808085QH251).

Conflict of Interest: None.

REFERENCES

1. Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017;31(3):373-396. doi: 10.1016/j.berh.2017.09.013
2. Rastin M, Mahmoudi M, Sahebami M. Clinical & immunological characteristics in systemic lupus erythematosus patients. Indian J Med Res. 2017;146(2):224-229. doi: 10.4103/ijmr.IJMR_1356_15
3. Ma ZZ, Sun HS, Lv JC, Guo L, Yang QR. Expression and clinical significance of the NEK7-NLRP3 inflammasome signaling pathway in patients with systemic lupus erythematosus. J Inflamm (Lond). 2018;15:16. doi: 10.1186/s12950-018-0192-9
4. Durcan L, Petri M. Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun. 2016;74:73-94. doi: 10.1016/j.jaut.2016.06.010
5. Oon S, Huq M, Godfrey T, Nikpour M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin Arthritis Rheum. 2018;48(2):221-239. doi: 10.1016/j.semarthrit.2018.01.001
6. Apostolopoulos D, Kandane-Rathnayake R, Raghnath S, Hoi A, Nikpour M, Morand EF. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med. 2016;3(1):e000157. doi: 10.1136/lupus-2016-000157
7. Kon T, Yamaji K, Sugimoto K, Ogawara M, Kenpe K, Ogawara H, et al. Investigation of pathological and clinical features of lupus nephritis in 73 autopsied cases with systemic lupus erythematosus. Mod Rheumatol. 2010;20(2):168-177. doi: 10.1007/s10165-009-0260-3
8. Karampetsou MP, Comte D, Suárez-Fueyo A, Katsuyama E, Yoshida N, Kono M, et al. SLAMF1 engagement inhibits T cell-B cell interaction and diminishes IL-6 production and plasmablast differentiation in systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(1):99-108. doi: 10.1002/art.40682
9. Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015;18(2):154-163. doi: 10.1111/1756-185X.12463
10. Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011
11. Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev. 2015;14(11):1095-1018. doi: 10.1016/j.autrev.2015.07.003
12. Felten R, Dervovic E, Chasset F, Gottenberg JE, Sibilia J, Scher F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17(8):781-790. doi: 10.1016/j.autrev.2018.02.011
13. Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic and toxicologic effects. Toxicol Sci. 2006;91(2):586-599. doi:10.1093/toxsci/kfj148

14. Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(3):75-85. doi: 10.1177/1759720X17690474

15. Frieri M, Heuser W, Bliss J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis. J Pharmacol Pharmacother. 2015;6(2):71-76. doi: 10.4103/0976-500X.155482

16. La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol. 2013;148(3):322-327. doi: 10.1016/j.clim.2012.11.010

17. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocytestimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066-1073. doi: 10.1172/JCI38010

18. Mok CC. Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art. Expert Rev Clin Immunol. 2017;13(7):677-692. doi:10.1080/1744666X.2017.1323635

19. Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, et al. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018;70(6):868-877. doi:10.1002/art.40439

20. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015;74(11):2006-2015. doi:10.1136/annrheumdis-2013-207564

21. Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, et al. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Arthritis Rheumatol. 2017;69(2):362-375. doi:10.1002/art.39856

22. Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(2):332-340. doi:10.1136/annrheumdis-2015-207654

23. Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review. J Pediatr. 2017;187:213-219. doi: 10.1016/j.jpeds.2017.05.002

24. Lenert A, Niewold TB, Lenert P. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther. 2017;11:747-757. doi: 10.2147/DDDT.S114552

Author’s Contribution:

MJT designed the study and conceived the survey. LRJ and LX collected epidemiological data. ZL and HP sorted the data. JZ and LX were involved in the fieldwork. MJT and PC conducted the analysis and wrote the first draft of the manuscript. The first two authors contributed equally to this work and are considered co-first authors. Hui Yuan evaluated the results and revised the manuscript, takes responsibility for the integrity of the research.

Authors:

1. Meng-Jun Tao,
2. Ping Cheng,
Administration Office of Education Cluster,
3. Lai-Run Jin,
4. Jun Zhou,
5. Wei Shi,
Hui Peng,
Administration Office of Hospital Admission and Discharge,
6. Hui Yuan,
1,3,5,9: Department of Epidemiology and Biostatistics, School of Public Health, Wannan Medical College, Wuhu, P.R. China.
2,6-8: Yijishan Hospital of Wannan Medical College, Wuhu, P.R. China.